Literature DB >> 20660383

Quantification of smoking-induced occupancy of beta2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding.

Irina Esterlis1, Kelly P Cosgrove, Jeffery C Batis, Frederic Bois, Stephanie M Stiklus, Evgenia Perkins, John P Seibyl, Richard E Carson, Julie K Staley.   

Abstract

UNLABELLED: 5-(123)I-iodo-85380 ((123)I-5-IA) is used to quantitate high-affinity nicotinic acetylcholine receptors (beta(2)-nAChRs) on human SPECT scans. The primary outcome measure is V(T)/f(P), the ratio at equilibrium between total tissue concentration (free, nonspecifically bound, and specifically bound) and the free plasma concentration. Nondisplaceable uptake (free plus nonspecific) of (123)I-5-IA has not been measured in human subjects. Nicotine has high affinity for beta(2)*-nAChRs (nAChRs containing the beta(2)* subunit, for which * represents other subunits that may also be part of the receptor) and displaces specifically bound (123)I-5-IA. In this study, we measured nicotine occupancy and nondisplaceable binding in healthy smokers after they had smoked to satiety.
METHODS: Eleven nicotine-dependent smokers (mean age +/- SD, 35.6 +/- 14.4 y) completed the study. One subject was excluded from subsequent analyses because of abnormal blood nicotine levels. Subjects abstained from tobacco smoke for 5.3 +/- 0.9 d and participated in a 15- to 17-h SPECT scanning day. (123)I-5-IA was administered by bolus plus constant infusion, with a total injected dose of 361 +/- 20 MBq. At approximately 6 h after the start of the infusion, three 30-min SPECT scans and a 15-min transmission-emission scan were acquired to obtain baseline beta(2)*-nAChR availability. Subjects then smoked to satiety (2.4 +/- 0.7 cigarettes), and arterial (first 40 min) and venous (until study completion) plasma nicotine and cotinine levels were collected. About 1 h after subjects had smoked to satiety, up to six 30-min SPECT scans were acquired. V(T)/f(P) data, computed from the tissue and plasma radioactivity measurements from the presmoking baseline and postsmoking scans, were analyzed using the Lassen plot method.
RESULTS: Receptor occupancy after subjects had smoked to satiety was 67% +/- 9% (range, 55%-80%). Nondisplaceable uptake was estimated as 19.4 +/- 5.8 mL x cm(-3) (range, 15-28 mL x cm(-3)). Thus, in the thalamus, where mean V(T)/f(P) is 93 mL x cm(-3), nondisplaceable binding represents approximately 20% of the total binding.
CONCLUSION: These results are in agreement with previous findings and suggest that when satiating doses of nicotine are administered to smokers, imaging of receptor availability can yield valuable data, such as quantifiable measures of nondisplaceable binding.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660383      PMCID: PMC3707518          DOI: 10.2967/jnumed.109.072447

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  37 in total

1.  Subjective and cardiovascular effects of intravenous nicotine in smokers and non-smokers.

Authors:  R Soria; J M Stapleton; S F Gilson; A Sampson-Cone; J E Henningfield; E D London
Journal:  Psychopharmacology (Berl)       Date:  1996-12       Impact factor: 4.530

2.  Imaging nicotinic acetylcholine receptors with fluorine-18-FPH, an epibatidine analog.

Authors:  V L Villemagne; A Horti; U Scheffel; H T Ravert; P Finley; D J Clough; E D London; H N Wagner; R F Dannals
Journal:  J Nucl Med       Date:  1997-11       Impact factor: 10.057

3.  [125/123I]IPH: a radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors.

Authors:  J L Musachio; V L Villemagne; U Scheffel; M Stathis; P Finley; A Horti; E D London; R F Dannals
Journal:  Synapse       Date:  1997-08       Impact factor: 2.562

4.  Higher levels of nicotine in arterial than in venous blood after cigarette smoking.

Authors:  J E Henningfield; J M Stapleton; N L Benowitz; R F Grayson; E D London
Journal:  Drug Alcohol Depend       Date:  1993-06       Impact factor: 4.492

5.  Chronic and acute tolerance to subjective effects of nicotine.

Authors:  K A Perkins; J E Grobe; L H Epstein; A Caggiula; R L Stiller; R G Jacob
Journal:  Pharmacol Biochem Behav       Date:  1993-06       Impact factor: 3.533

6.  2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling.

Authors:  A O Koren; A G Horti; A G Mukhin; D Gündisch; A S Kimes; R F Dannals; E D London
Journal:  J Med Chem       Date:  1998-09-10       Impact factor: 7.446

7.  Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia.

Authors:  A Nordberg; I Alafuzoff; B Winblad
Journal:  J Neurosci Res       Date:  1992-01       Impact factor: 4.164

8.  In vivo studies with [125I]5-I-A-85380, a nicotinic acetylcholine receptor radioligand.

Authors:  D B Vaupel; A G Mukhin; A S Kimes; A G Horti; A O Koren; E D London
Journal:  Neuroreport       Date:  1998-07-13       Impact factor: 1.837

9.  Nicotinic receptor desensitization and sensory gating deficits in schizophrenia.

Authors:  J M Griffith; J E O'Neill; F Petty; D Garver; D Young; R Freedman
Journal:  Biol Psychiatry       Date:  1998-07-15       Impact factor: 13.382

10.  Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors.

Authors:  M A Abreo; N H Lin; D S Garvey; D E Gunn; A M Hettinger; J T Wasicak; P A Pavlik; Y C Martin; D L Donnelly-roberts; D J Anderson; J P Sullivan; M Williams; S P Arneric; M W Holladay
Journal:  J Med Chem       Date:  1996-02-16       Impact factor: 7.446

View more
  24 in total

1.  Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia.

Authors:  James Robert Brašić; Nicola Cascella; Anil Kumar; Yun Zhou; John Hilton; Vanessa Raymont; Andrew Crabb; Maria Rita Guevara; Andrew G Horti; Dean Foster Wong
Journal:  Synapse       Date:  2011-12-29       Impact factor: 2.562

2.  Sex differences in availability of β2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers.

Authors:  Kelly P Cosgrove; Irina Esterlis; Sherry A McKee; Frederic Bois; John P Seibyl; Carolyn M Mazure; Suchitra Krishnan-Sarin; Julie K Staley; Marina R Picciotto; Stephanie S O'Malley
Journal:  Arch Gen Psychiatry       Date:  2012-04

3.  Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.

Authors:  Aybala Saricicek; Irina Esterlis; Kathleen H Maloney; Yann S Mineur; Barbara M Ruf; Anjana Muralidharan; Jason I Chen; Kelly P Cosgrove; Rebecca Kerestes; Subroto Ghose; Carol A Tamminga; Brian Pittman; Frederic Bois; Gilles Tamagnan; John Seibyl; Marina R Picciotto; Julie K Staley; Zubin Bhagwagar
Journal:  Am J Psychiatry       Date:  2012-08       Impact factor: 18.112

4.  Smoking normalizes cerebral blood flow and oxygen consumption after 12-hour abstention.

Authors:  Manouchehr S Vafaee; Albert Gjedde; Nasrin Imamirad; Kim Vang; Mallar M Chakravarty; Jason P Lerch; Paul Cumming
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-31       Impact factor: 6.200

5.  Imaging changes in synaptic acetylcholine availability in living human subjects.

Authors:  Irina Esterlis; Jonas O Hannestad; Frederic Bois; R Andrew Sewell; Rachel F Tyndale; John P Seibyl; Marina R Picciotto; Marc Laruelle; Richard E Carson; Kelly P Cosgrove
Journal:  J Nucl Med       Date:  2012-11-15       Impact factor: 10.057

6.  Assessing the sensitivity of [¹¹C]p943, a novel 5-HT1B radioligand, to endogenous serotonin release.

Authors:  Kelly P Cosgrove; Tracy Kloczynski; Nabeel Nabulsi; David Weinzimmer; Shu-Fei Lin; Julie K Staley; Zubin Bhagwagar; Richard E Carson
Journal:  Synapse       Date:  2011-05-03       Impact factor: 2.562

7.  Smoking and Neuroimaging: A Review.

Authors:  Hedy Kober; Cameron M Deleone
Journal:  Curr Cardiovasc Risk Rep       Date:  2011-12-01

8.  Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder.

Authors:  Jeffrey M Miller; Natalie Hesselgrave; R Todd Ogden; Gregory M Sullivan; Maria A Oquendo; J John Mann; Ramin V Parsey
Journal:  Biol Psychiatry       Date:  2013-03-01       Impact factor: 13.382

9.  Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers.

Authors:  Irina Esterlis; Jonas O Hannestad; Evgenia Perkins; Frederic Bois; D Cyril D'Souza; Rachel F Tyndale; John P Seibyl; Dorothy M Hatsukami; Kelly P Cosgrove; Stephanie S O'Malley
Journal:  Am J Psychiatry       Date:  2013-04       Impact factor: 18.112

Review 10.  Dual role of nicotine in addiction and cognition: a review of neuroimaging studies in humans.

Authors:  Agnes J Jasinska; Todd Zorick; Arthur L Brody; Elliot A Stein
Journal:  Neuropharmacology       Date:  2013-03-06       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.